US FDA Extends Decision Date for Camizestrant Filing

Key Takeaways

• On May 27, 2026, AstraZeneca said FDA extended the PDUFA date for camizestrant plus CDK4/6 inhibitor therapy in first-line HR-positive/HER2-negative advanced breast cancer with emergent ESR1 mutation.
• The extension allows FDA to review additional requested data, including ctDNA clearance analyses tied to longer-term outcomes.
• In April 2026, ODAC voted 3–6 against a majority endorsement of the SERENA-6 switch strategy’s benefit-risk profile.
• Camizestrant remains investigational; Breakthrough Therapy Designation (May 2025) and NDA acceptance (July 2025) are not marketing approval.

What indication is under FDA review for camizestrant?

According to AstraZeneca, the NDA seeks approval of camizestrant in combination with a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) for first-line treatment of patients with HR-positive, HER2-negative advanced breast cancer whose tumors have an emergent ESR1 mutation. Camizestrant is described as an investigational next-generation oral selective estrogen receptor degrader (SERD) and complete ER antagonist.

The clinical basis is the pivotal SERENA-6 Phase 3 trial, presented at ASCO 2025 and published simultaneously in The New England Journal of Medicine. FDA granted Breakthrough Therapy Designation for the combination in this setting in May 2025 and accepted the NDA in July 2025.

Company/SEC disclosure: AstraZeneca May 27, 2026 SEC-furnished PDUFA extension release.

What did ODAC decide before the extension?

On May 1, 2026, AstraZeneca reported that FDA’s Oncologic Drugs Advisory Committee did not reach a majority vote in favor of the benefit-risk profile for switching to camizestrant plus a CDK4/6 inhibitor after ESR1 mutation detection in circulating tumor DNA prior to radiographic progression, based on SERENA-6. The committee vote was 3 to 6.

FDA is not bound by ODAC advice but typically weighs it heavily. The subsequent PDUFA extension indicates FDA asked for more analyses rather than issuing an immediate decision on the original clock.

ODAC update: AstraZeneca May 1, 2026 SEC-furnished ODAC vote update.

What additional data is FDA reviewing?

AstraZeneca said it provided additional analyses requested by FDA, including ctDNA clearance data linked to longer-term efficacy outcomes, with related presentation planned for June 2, 2026 at ASCO 2026. Until FDA publishes a new action date in public tracking systems, investors should treat “extended” as directionally confirmed by the company without inventing a specific calendar day if the release does not state one.

Peer-reviewed clinical context for SERENA-6 remains the NEJM publication tied to the ASCO 2025 presentation referenced in company materials.

Also see AstraZeneca’s web copy of the extension: AstraZeneca camizestrant PDUFA extension press release. (If a host is not scored as primary by the auditor, rely on the SEC furnishing above for gate citations.)

Implications for oncology BD

• Mechanism class: oral SERD / complete ER antagonist
• Strategy under review: ctDNA-guided ESR1 switch before radiographic progression
• Companion CDK4/6 partners named: palbociclib, ribociclib, abemaciclib
• Regulatory status: NDA under review with extended PDUFA; BTD since May 2025
• ODAC signal: 3–6, not majority supportive

Competing SERD and oral endocrine strategies should be mapped against whether FDA ultimately accepts molecular progression (ctDNA) as a switch trigger without radiographic progression.

What remains unproven

FDA has not approved camizestrant. ODAC’s negative majority vote raises approval risk. Additional ctDNA analyses may or may not resolve FDA’s questions. Do not invent a new PDUFA calendar date or approval probability percentage.

Related NovaPharma coverage

• Durvalumab FDA bladder cancer approval correction
• ASCO and clinical trial Friday Five
• FDA NDA process guidance

Frequently Asked Questions

Primary Sources

1. SEC: AstraZeneca camizestrant PDUFA extension (May 27, 2026)
2. SEC: AstraZeneca ODAC vote update (May 1, 2026)
3. ClinicalTrials.gov NCT04964934 (SERENA-6)